Navigation Links
Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding Trabectedin for Relapsed Ovarian Cancer
Date:7/15/2009

HORSHAM, Pa., July 15 /PRNewswire/ -- Based on the data presented today, the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended that the combination of trabectedin when administered with DOXIL(R) (doxorubicin HCI liposome injection) did not provide a sufficient benefit-risk profile for the treatment of relapsed ovarian cancer.

Ovarian cancer is difficult to treat and the disease often recurs in patients who previously have been treated with platinum-based therapy, underscoring the need for non-platinum treatment options. Centocor Ortho Biotech Products continues to believe trabectedin has an important role in the treatment of recurrent ovarian cancer. The company remains committed to working with the FDA to address the committee's concerns.

The committee provides non-binding recommendations based on its evaluation. The final decision regarding approval of the drug will be made by the FDA.

About Trabectedin

Trabectedin is a novel cytotoxic antitumor agent that was originally derived from the marine tunicate, Ecteinascidia turbinata. The compound is now produced synthetically. Trabectedin binds to the minor groove of DNA and bends it toward the major groove, causing DNA adducts that interfere with cell division and genetic transcription processes and DNA repair machinery. Under a licensing agreement with PharmaMar SAU of Spain, Centocor Ortho Biotech Products, L.P. has worldwide marketing rights for trabectedin except in Europe and Japan, where the product is marketed as YONDELIS(R) by PharmaMar SAU.

About Centocor Ortho Biotech Products, L.P.

Centocor Ortho Biotech redefines the standard of care in immunology, nephrology, and oncology. The company was formed when Centocor, Inc. and Ortho Biotech Products, L.P. were consolidated in late 2008, and was re
'/>"/>

SOURCE Centocor Ortho Biotech Products, L.P.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
2. Centocor, Inc. Submits Application to FDA Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
3. MEDVERSATION(TM) Website Launched by Centocor to Facilitate Physician-Patient Dialogue About Drug Benefits and Risks
4. Biologic Drugs, Particularly Centocor/Janssen-Cilags Stelara and Abbott/Eisais Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017
5. FASgen, Inc. Announces Research and License Agreement With Centocor, Inc.
6. Centocor R&D and University of Michigan Forge New Model for Academic/Industry Partnerships
7. Zimmer Holdings Offer and ORTHOsoft Directors Circular Mailed to Shareholders
8. David Ward Joins OrthoSynetics(TM) as Western Region Sales Manager
9. OrthoSynetics(TM) Opens New Data Center, Colocation Facility
10. Bone-growing nanomaterial could improve orthopaedic implants
11. Orthopedic Development Corporations TruFUSE(R) Procedure Tops 1,750 Patients in First Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... Spring, PA (PRWEB) April 21, 2015 ... Berks County commercial printer, Offset Impressions. , ... its full line of printing capabilities and knowledgeable team ... “This acquisition allows us to offer an ever ... to the labeling, packaging, and specialty services we already ...
(Date:4/21/2015)... The California Healthcare Institute (CHI), ... sciences organizations, released the following statement by CHI ... Assembly Bill (AB) 463: , “As innovators in ... of treatments and cures for patients with serious ... AB 463, the so-called Pharmaceutical Cost Transparency Act ...
(Date:4/21/2015)... 2015 Information is the best weapon in ... FACP, empowers patients and their families with knowledge about living ... and Cancer is the Answer" and new website . ... to guide patients from diagnosis through treatment and even death. ... in their treatment, at home and in the examination room. ...
(Date:4/21/2015)... 21, 2015 The report ... comparative analysis on the therapeutic development for ... by identifying new targets and MOAs to ... with TOC is available @ http://www.rnrmarketresearch.com/dermatitis-pipeline-review-h1-2015-market-report.html ... key players involved in the therapeutic development ...
(Date:4/21/2015)... 2015 The 2015 Market Research ... a professional and in-depth study on the current ... with a focus on the Chinese situation. ... citrate market research are Cargill, Fbc Industries, Posy ... Biochemical, Capchem, Lianyungang Mupro Fi, Yixing-Union, Debang Fine ...
Breaking Medicine News(10 mins):Health News:California Healthcare Institute Statement on AB 463 2Health News:California Healthcare Institute Statement on AB 463 3Health News:Authoritative guide and new accompanying therapeutic web portal bridge information gaps in cancer treatment 2Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4Health News:Sodium Citrate Industry Global Key Manufacturers Analysis Report 2015-2020 2Health News:Sodium Citrate Industry Global Key Manufacturers Analysis Report 2015-2020 3
... LONDON, Nov. 25 Cephalon, Inc.,(Nasdaq: CEPH ... today announced that the companies have signed an Option ... worldwide license to,the investigational medication Lupuzor(TM) for the treatment ... large Phase IIb study of,Lupuzor in patients in Europe ...
... Calif., Nov. 25 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ... biopharmaceutical,company developing monoclonal antibodies for the treatment ... that the U.S. Patent and Trademark,Office has ... includes broad,claims covering anti-viral applications of antibodies ...
... ARNA ) announced today that the company is ... Conference on December 3, 2008 at 2:30,p.m. Eastern Time (11:30 ... York City. Jack Lief, Arena,s President and Chief Executive Officer, ... clinical,development and discovery programs. , ...
... a new,commercial finance company that will focus on middle market ... with over $500,million in equity commitments. MidCap,s investors are ... Moelis Capital Partners. MidCap,also has a substantial long-term debt ... Fargo & Company (NYSE: WFC ). , ...
... NEW YORK, Nov. 25 When Professional Basketball player Steve ... Gold Medal Snowboarder Gretchen Bleiler, Gold Medal Swimmer Amanda Beard and ... the slopes or enter an arena, it,s hard to ... , Besides being some of the world,s most accomplished ...
... Inc., a leader in the development and commercialization of ... the AIGISRx(TM) Anti-bacterial Envelope following its commercialization ... anti-bacterial surgical mesh developed to deliver anti-microbial agents that ... and cardioverter defibrillators. , ...
Cached Medicine News:Health News:Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication 2Health News:Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication 3Health News:Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication 4Health News:Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies 2Health News:Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies 3Health News:Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies 4Health News:Arena Pharmaceuticals to Present at the Piper Jaffray 20th Annual Health Care Conference 2Health News:Arena Pharmaceuticals to Present at the Piper Jaffray 20th Annual Health Care Conference 3Health News:MidCap Financial Launches Commercial Finance Company With Over $500 Million of Equity 2Health News:MidCap Financial Launches Commercial Finance Company With Over $500 Million of Equity 3Health News:MidCap Financial Launches Commercial Finance Company With Over $500 Million of Equity 4Health News:MidCap Financial Launches Commercial Finance Company With Over $500 Million of Equity 5Health News:Top Athletes Join Forces for a New Mission: Athlete-Engineered Skincare to Support Performance and Benefit Charity 2Health News:Top Athletes Join Forces for a New Mission: Athlete-Engineered Skincare to Support Performance and Benefit Charity 3Health News:TYRX, Inc. Announces 1,000th Implant of AIGISRx(TM) Anti-Bacterial Envelope 2Health News:TYRX, Inc. Announces 1,000th Implant of AIGISRx(TM) Anti-Bacterial Envelope 3Health News:TYRX, Inc. Announces 1,000th Implant of AIGISRx(TM) Anti-Bacterial Envelope 4
(Date:4/21/2015)... -- Organovo Holdings, Inc. (NYSE MKT: ONVO) today announced preliminary ... year ended March 31, 2015. Based on ... March 31, 2015, Organovo estimates: , Total ... and approximately $571 thousand for the fiscal year , ... and fiscal year ended March 31, 2015 of approximately ...
(Date:4/21/2015)... 21, 2015 Algae International Group, Inc. ( ALGA ... Company, today announced exceptional Hempster T-Shirt sales following yesterday,s ... Oil Company has introduced four t-shirt designs specific to ... the profit from the online sales of these first ... will be donated to the  Marijuana Policy Project  (MPP), ...
(Date:4/21/2015)... 21, 2015 Global cap & ... demand for caps and closures will exceed $55 billion in ... two trillion annually. Beverages will continue to account for well ... a number of smaller markets are expected to register faster ... Although the most developed markets -- the US, ...
Breaking Medicine Technology:Organovo Holdings, Inc. Pre-Announces Preliminary Fiscal 2015 Fourth Quarter And Year End Financial Information 2Organovo Holdings, Inc. Pre-Announces Preliminary Fiscal 2015 Fourth Quarter And Year End Financial Information 3Organovo Holdings, Inc. Pre-Announces Preliminary Fiscal 2015 Fourth Quarter And Year End Financial Information 4American Seed & Oil Company 420 Hempster T-Shirt Sales Soar; Online Sales Launched Yesterday with Start of 420 Week; Over 2000 Shirts Sold So Far 2World Caps & Closures Market 2World Caps & Closures Market 3
... Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) disclosed today ... (HCV) infected patients with the Aethlon Hemopurifier® will be ... of the American Society of Nephrology (ASN). Dr. Vijay ... of Nephrology at the Fortis Hospital in New Delhi, ...
... LAUSANNE, Switzerland, October 15 Biocartis ... molecular and,immunodiagnostics based on its proprietary micro-technology platform, today,announced ... round. The,Company raised EUR 10 million ( USD 14.9 ... The deal was led by ...
Cached Medicine Technology:Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference 2Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference 3Biocartis Raises EUR10 Million in Series A Financing Round 2Biocartis Raises EUR10 Million in Series A Financing Round 3
Ambion's barrier tips prevent cross-contamination of samples by means of an aerosol filter. They are RNase- and DNase-free and are ideal for handling RNA, PCR applications, and for working with radio...
This large 1000 L tip makes pipetting fragile cells, genomic DNA, and viscous samples easy. Perfect for cell culture laboratories....
300 L, Bulk Recommended for 250 and 300 L pipettes....
Designed to fit a variety of 250 L and 300 ul multi-channel pipettors, this tip offers a secure fit and extra space for repeat pipetting....
Medicine Products: